Mobile

A study Comparing SB8 to Avastin in Subjects with Lung Cancer (Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer)

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004026-34

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the equivalence of SB8 to Avastin®, in terms of the best overall response rate (ORR) by 24 weeks of chemotherapy in subjects with metastatic or recurrent non squamous NSCLC.

Critère d'inclusion

  • The intended use of SB8 is the treatment of metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)

Liens